Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines
Parexel experts from regulatory, epidemiology and biostatistics discuss the use of external control arms (ECAs) as an alternative to randomized controlled trials (RCTs) to accelerate clinical development. Based on literature analysis, as well as available EMA and FDA guidelines, they provide a detailed assessment of ECAs pros and cons.
The digital era has enhanced the potential for real-world evidence (RWE) in regulatory decision-making, as demonstrated during the COVID-19 pandemic. Artificial intelligence (AI) could play a crucial role in analyzing RWE data to identify trends and important factors to control, potentially expanding ECA applications to dosage optimization, new administration routes, and accelerated treatment development. However, ECA implementation based on RWD still remains limited due to challenges such as ensuring data robustness, matching patient populations, and controlling bias.
What is more, regulatory acceptance of ECAs also requires thorough justification and early discussions with authorities to address potential biases and confounding factors. Therefore, while ECAs have the potential to streamline drug development and bring treatments to patients faster, further advancements in regulatory approaches, methodologies, and technologies are necessary to realize this goal fully.
Related Insights
Blog
Regulatory acceptability of AI: Current perspectives
Mar 7, 2024
Blog
The future of drug development: Leveraging EMA support for use of alternative nonclinical approaches
Jun 6, 2024
Blog
AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression
Mar 19, 2024
Blog
Summary and assessment: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback (FDA)
Mar 7, 2024
Blog
Summary and assessment of EMA’s reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle
Mar 7, 2024
Whitepaper
Biosimilar development: Optimizing PK/PD studies
Mar 28, 2025
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Related Insights
Blog
Regulatory acceptability of AI: Current perspectives
Mar 7, 2024
Blog
The future of drug development: Leveraging EMA support for use of alternative nonclinical approaches
Jun 6, 2024
Blog
AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression
Mar 19, 2024
Blog
Summary and assessment: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback (FDA)
Mar 7, 2024
Blog
Summary and assessment of EMA’s reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle
Mar 7, 2024
Whitepaper
Biosimilar development: Optimizing PK/PD studies
Mar 28, 2025
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023